Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
APSP J Case Rep ; 4(2): 23, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24040601

RESUMEN

Mediastinal teratomas are rarely reported in children. We report a 12-year-old child, diagnosed and treated as empyema thoracis in a peripheral setting for 18 months. In our centre, CT scan performed revealed a well circumscribed multiloculated cystic lesion containing fat, bone and teeth, suggestive of a teratoma. The mass was excised and found to be an infected posterior mediastinal teratoma, confirmed on histopathology.

3.
Indian Pediatr ; 49(2): 139-43, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22410513

RESUMEN

Retinopathy of prematurity (ROP) is a disorder of neonatal retinal vascularization. The incidence is increasing in developing countries like India in view of the rising numbers of preterm deliveries and improved neonatal care. Traditional modalities of treatment included cryotherapy and laser therapy, which were laborious and required special training. Hence, research is on way to find novel treatment modalities directed at various levels of pathogenesis for this blinding disease. We reviewed the published and unpublished literature on newer methods of ROP management. The pathogenesis of ROP has been studied with respect to the mediators of angiogenesis. Anti vascular endothelial growth factor (Anti-VEGF) therapy has been extensively studied and the studies have demonstrated its promising role early stages of ROP. The role of Insulin like growth factor (IGF), Granulocyte colony stimulating factor (GCSF), and June kinases (JNK) inhibitors are being studied by various researchers across the world. Gene therapy holds promise in the reversal of ROP changes.


Asunto(s)
Retinopatía de la Prematuridad/terapia , Terapia Genética , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Humanos , Recién Nacido , Recien Nacido Prematuro , Proteína Quinasa 8 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 8 Activada por Mitógenos/uso terapéutico , Somatomedinas/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Factor A de Crecimiento Endotelial Vascular/uso terapéutico
4.
Curr Treat Options Gastroenterol ; 2(2): 97-103, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11096579

RESUMEN

More than 80% of cases of amebic liver abscess can be managed with a 14-day course of intravenous or oral metronidazole. In cases of suspected amebic liver abscess, treatment should be started before diagnostic confirmation. If no clinical improvement is evident by 72 to 96 hours, treatment should be changed to dehydroemetine and chloroquine. Invasive treatment is necessary only in patients in whom medical treatment fails within 5 days or in whom signs of clinically severe disease are present. A 10-day course with a luminal agent such as paromomycin to eliminate intestinal cysts, which are resistant to imidazoles, should always follow treatment of the liver abscess. Percutaneous catheter drainage is indicated in patients with impending rupture, with a lesion 6 cm or more in diameter, with an abscess located in the left lobe or high in the dome of the right lobe, or in whom medical treatment fails. Although sympathetic pleural effusion is not an indication for drainage, direct pulmonary involvement or spread to pleural or lung tissues requires drainage. Intraperitoneal rupture and peritonitis necessitate open surgical drainage. Only a small minority of amebic liver abscesses are secondarily infected by other organisms. Because relapses are possible, feces should be checked for cysts monthly for several months after therapy.

5.
Phys Rev B Condens Matter ; 39(12): 8757-8759, 1989 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-9947599
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...